

# Case studies from SEURAT-1 **DETECTIVE**

**Jos Kleijnans**

*Dept of Toxicogenomics  
Maastricht University*

# Increasing demands on chemical risk assessment

- High failure rate of new drug candidates due to unmanageable toxicity, accounting for approximately 30% of this attrition
- The EU REACH program on industrial chemicals
  - Existing and new substances should in the future be subject to the same procedure under a single system.
  - Large amounts of additional tests required before 2018
  - 30,000 existing chemicals already placed on the market since before 1981 and sold at > 1 tonne per year
- EU-wide ban on animal use in cosmetics development.
  - European Community Cosmetics Directive (Directive 76/768/EEC) and its 7th Amendment (2003/15/EC)



**BUILDING BLOCKS:**  
 construction of a solid  
 foundation in an  
 integrated approach of  
 six research projects  
 (“building blocks”),  
 each dedicated to a  
 specific topic:

# Safety Evaluation Ultimately Replacing Animal Testing



Stem cell differentiation for providing human-based organ specific target cells to assay toxicity pathways *in vitro*



Development of a hepatic microfluidic bioreactor mimicking the complex structure and function of the human liver



Identification and investigation of human biomarkers in cellular models for repeated dose *in vitro* testing



Delivery of an integrated suite of computational tools to predict the effects of long-term exposure to chemicals in humans based on *in silico* calculations



Development of systems biological tools for organotypic human cell cultures suitable for long term toxicity testing and the identification and analysis of pathways of toxicological relevance



Data management, cell and tissue banking, selection of reference compounds and chemical repository



Cluster level coordinating and support action


## Detection of endpoints and biomarkers for repeated dose toxicity using *in vitro* systems

- DETECTIVE will set up a screening pipeline of functional and “-omics” technologies, including high content and high throughput screening platforms, to develop and investigate human biomarkers for repeated dose toxicity in cellular *in vitro* models.
  - Emphasis will be put on the systematic exploitation of functional and “-omics” readouts, including high content and high throughput screening platforms.
  - While functional parameters give more insights into the effects of toxicants on specific cell functions of interest, “-omics” techniques will deliver data on the entire cellular situation at the molecular level.
- DETECTIVE will perform for the first time an in-depth investigation of repeated dose effects on epigenetics and microRNA (miRNA) expression thus exploring whether such analyses deepen our understanding of toxic modes of action.





# Organ models


1. Kidney model:  
RPTEC/TERT1 cells:  
human renal proximal  
tubule cell line




2. Heart model:  
human induced  
pluripotent stem (iPS)  
cardiomyocytes



3. Liver model:  
primary human  
hepatocytes, HepaRG,  
HepG2



# Integration of transcriptomics, proteomics, metabonomics with epigenetics and $\mu$ RNA and bioinformatics in predictive toxicology



# Main hypothesis:


Toxicant-induced changes in molecular networks which persist after terminating repeated dosing *in vitro*, present promising biomarkers for repeated dose toxicity in humans

# Liver experiments @UM

- 1) “Assessment of repeated dose toxicity of valproic acid in the human liver using integrative ‘-omics’ data analyses”  
→ integrated data analyses of DNA methylation, gene expression and miRNAs in order to find novel mechanisms of VPA induced liver steatosis
- 2) “Assessment of repeated dose toxicity of aflatoxin B1 (AFB1) in the human liver using integrative ‘-omics’ data analyses”  
→ integrated data analyses of DNA methylation, gene expression and miRNAs in order to find novel mechanisms of AFB1 induced liver carcinogenesis
- 3) “Assessment of repeated dose toxicity of cyclosporin A in the human liver using integrative ‘-omics’ data analyses”  
→ integrated data analyses of DNA methylation, gene expression and miRNAs in order to find novel mechanisms of CsA induced liver cholestasis

# Liver model: primary human hepatocytes:

- Commercially available
- Cryopreserved platable hepatocytes: pool of 3 different human donors
- High viability
- Cultured in two-layer collagen sandwich model
- Cells show *in vivo* like configuration
- *In vivo*-like enzyme expression levels



# Assessment of repeated dose toxicity of valproic acid in pooled human primary hepatocytes using integrative 'omics data analyses

- VPA is known to induce liver steatosis, presumably through oxidative stress
- inhibits the enzyme histone deacetylase 1, thereby inducing histone hyperacetylation
- stimulates active demethylation in a replication independent manner by increasing accessibility of demethylase enzyme
- effects on mRNA and miRNA expression



# Analyses

## 1. DNA methylation analyses

NimbleGen 2.1M Deluxe Promoter  
 Array Medip-Chip

Format: 2.1M Source: UCSC Probe Length: 50-75mer Median Probe Spacing: 100bp Recommended Storage: Store arrays desiccated at room temperature					
Description	Build	Promoter Upstream Tiling (bp)	Promoter Downstream Tiling (bp)	Number of CpG Islands	miRNA Promoters
<b>NEW!</b> Human DNA Methylation 2.1M Deluxe Promoter v2 Array	HG19	8000**	3000	27867	730 (~15kb to mature miRNA)



## 2. Transcriptomics

Affymetrix Human Genome U133 Plus  
 2.0 GeneChip arrays Human Genome  
 U133 Set plus 6,500 additional genes  
 for analysis of over 47,000 transcripts



## 3. miRNA analyses


Agilent Human miRNA Microarray  
 Release 19.0, 8x60K based on miRBase.  
 2006 human miRNAs represented.



Ongoing

## 4. Analysis of steatosis


collagen-sandwiched pooled PHH ( 3 donors)  
 were stained with BODIPY (green) to  
 visualize intracellular lipid droplets



# Identification of differentially methylated (DMG) and differentially expressed genes (DEG) after 5 days of VPA exposure

	DMG	DEG
Settings	Magnitude >0 or <0; p-value <0.01 FDR <0.05	P-value <0.05; FDR <0.05; FC >1.5 or <-1.5
	8226	1932
	9305	1478
<b>Total</b>	<b>17531</b>	<b>3410 (7997 no FC)</b>


**Metacore™ pathway analyses of 6636 genes:  
 67 significant pathways (P <0.05). Top 10:**



Immune response_IL-13 signaling via PI3K-ERK
Cholesterol Biosynthesis
Development_Growth hormone signaling via PI3K/AKT and MAPK cascades
Apoptosis and survival_Endoplasmic reticulum stress response pathway
Histidine-glutamate-glutamine metabolism
Development_Angiotensin signaling via STATs
Mitochondrial ketone bodies biosynthesis and metabolism
Propionate metabolism p.2
Development_IGF-1 receptor signaling
Aminoacyl-tRNA biosynthesis in cytoplasm

# Persistence of epigenetic changes: comparison of 5 days of exposure with washout after 3 days

## Pathway analyses of 4082 persistently methylated genes using Metacore™



- Twenty pathways:  
 $P < 0.05 \rightarrow$  2 pathways involved in lipid metabolism; but also: DNA damage, apoptosis, cytoskeleton remodeling, immune response, cell adhesion.
- Lipid metabolism: fatty acid omega oxidation


# Assessment of repeated dose toxicity of AflatoxinB1 in pooled human primary hepatocytes using integrative 'omics data analyses

- Hepatotoxic and carcinogenic mycotoxin
  - Acute: apoptosis of liver cells and bile duct proliferation (Aflatoxicosis)
  - Chronic: hepatocellular carcinoma
- AFB1 exposure is associated with global hypomethylation and gene specific hypermethylation

# Analyses

## 1. DNA methylation analyses

NimbleGen 2.1M Deluxe Promoter Array  
Medip-Chip

 <b>Format:</b> 2.1M <b>Source:</b> UCSC <b>Probe Length:</b> 50-75mer <b>Median Probe Spacing:</b> 100bp <b>Recommended Storage:</b> Store arrays desiccated at room temperature					
Description	Build	Promoter Upstream Tiling (bp)	Promoter Downstream Tiling (bp)	Number of CpG Islands	miRNA Promoters
<b>NEW!</b> Human DNA Methylation 2.1M Deluxe Promoter v2 Array	HG19	8000**	3000	27867	730(-15kb to mature miRNA)



## 2. Transcriptomics

Affymetrix Human Genome U133 Plus 2.0  
GeneChip arrays

Human Genome U133 Set plus 6,500 additional  
genes for analysis of over 47,000 transcripts



## 3. miRNA analyses

Agilent Human miRNA Microarray Release 19.0,  
8x60K based on miRBase.  
2006 human miRNAs represented.



(Integrated)  
data analyses



# Results: numbers of modulated genes

Number of DMGs, DEGs, and DE-miRNAs in PHH after 5 days of exposure to the high dose (1  $\mu$ M) and low dose (0.3125  $\mu$ M) of AFB1, and after a washout of 3 days

	High dose					Low dose					
Direction of effect*	DMG	DEG		DE-miRs		DMG	DEG		DE-miRs		
	Magnitude >0 or <0; p-value <0.01 FDR <0.05	P-value <0.05; FDR <0.05; FC >1.5 or <-1.5		P-value <0.05; FDR <0.05; FC >1.5 or <-1.5		Magnitude >0 or <0; p-value <0.01 FDR <0.05	P-value <0.05; FDR <0.05; FC >1.5 or <-1.5		P-value <0.05; FDR <0.05; FC >1.5 or <-1.5		
	5 days	5 days	washout	5 days	washout	5 days	washout	5 days	washout	5 days	washout
+	2511	1399	896	15	8	1896	4397	702	368	0	0
-	2491	1156	1069	4	8	3743	3734	788	528	0	0
Total	5002	2555	1965	19	17	5639	8131	1490	896	0	0

\*direction of effect:

+ = DNA hypermethylation; gene expression upregulation; miRNA expression upregulation


- = DNA hypomethylation; gene expression downregulation; miRNA expression downregulation




# Identification of persistent, reversible and newly expressed DE-miRs

	DE-miRs persistent during washout	DE-miRs reversible during washout	DE-miRs newly emerging during washout
<b>Total</b>	4	15	13
<b>Down-regulated</b>	2	2	7
<b>Up-regulated</b>	2	13	6

# Integrated data analysis using networks



# Identification of regulatory miRNA-gene interactions




# Identification of regulatory miRNA-gene interactions

## Persistent effects microRNA


hsa-miR-34b-5p

hsa-miR-222-3p

## A priori known HCC related genes




## Novel HCC related genes




- In general changes on the microRNA level are not as persistent as on the mRNA level and are therefore more dynamic since they are much more dependent on the circumstances within a cell.
- 4 miRNAs are persistently expressed, of which two could be assigned to the network.
- Transcription of the persistently expressed microRNA hsa-miR-34b-5p has been shown to be directly induced by p53 in response to genotoxic stress, acting upon downstream targets to promote cell cycle arrest or apoptosis. In several in vitro cells models, increased expression of hsa-miR-34b-5p was observed following exposure to other genotoxic stressors (e.g. cyclo-phosphamide and benzo(a)pyrene. Hsa-miR-34b-5p is furthermore able to affect hundreds of genes involved in tumor development, among for example HCC.


## New effects microRNA



## Novel HCC related genes




# Identification of regulatory miRNA-gene interactions






# Identification of regulatory miRNA-gene interactions






# Identification of regulatory miRNA-gene interactions



# Identification of regulatory miRNA-gene interactions



# A) 2 persistently hypermethylated - downregulated genes and B) 16 persistently hypomethylated – upregulated genes, following 5 days of exposure to 0.3 µM of AFB1 and 3 days of wash-out

A.

Entrez Gene ID	Gene name	FC 5D	p-val 5D	FC WO	p-val WO
10974	ADIRF	-1.7305	0.0021	-2.1523	0.0000
6768	ST14	-1.5584	0.0055	-1.5868	0.0002

B.

Entrez Gene ID	Gene name	FC 5D	p-val 5D	FC WO	p-val WO
5111	PCNA	2.1010	0.0044	1.7179	0.0000
7296	TXNRD1	2.2622	0.0031	1.6844	0.0000
8812	CCNK	1.6374	0.0021	1.5481	0.0000
81624	DIAPH3	1.6981	0.0125	1.5173	0.0002
5874	RAB27B	2.7440	0.0029	2.7740	0.0000
8343	HIST1H2BF	2.5235	0.0025	1.8298	0.0000
8351	HIST1H3D	3.5308	0.0018	2.7170	0.0000
5678	PSG9	1.9268	0.0125	1.8668	0.0030
84675	TRIM55	1.6709	0.0045	1.8220	0.0000
51232	CRIM1	1.7854	0.0066	1.7126	0.0001
169792	GLIS3	1.7870	0.0035	1.6761	0.0000
90627	STARD13	1.7390	0.0031	1.6230	0.0000
196	AHR	1.8178	0.0398	1.5874	0.0032
11167	FSTL1	1.7953	0.0019	1.5646	0.0001
3486	IGFBP3	1.7002	0.0027	1.5607	0.0000
9173	IL1RL1	2.1095	0.0064	1.5003	0.0002

- DNA damage response
- Cell growth
- Metastatic events

# Conclusions

- By applying integrative cross-omics analyses to an innovative cell model in a repeated dose regime, we have unraveled molecular networks persistently affected by prototypical toxicants
  - VPA and AFB1 in the liver model
  - Doxorubicine in the heart model
  - Ochratoxin and potassium bromide in the kidney model
- Promising biomarkers for repeated dose toxicity in humans have been identified
- Follow-up is required which in particular consider
  - Larger numbers of chemicals for training and validating the predictive models
  - Physiologically relevant doses
  - Translation to molecular human disease signatures

# Acknowledgements



## Maastricht University

### Department of Toxicogenomics

- Simone van Breda
- Theo de Kok
- Sandra Claessen
- Marcel van Herwijnen
- Karen Brauers
- Daniël Theunissen
- Danyel Jennen
- Linda Rieswijk

### DETECTIVE partners and contributors

- Paul Jennings (IMU)
- Alice Limonciel (IMU)
- Agapios Sachinidis (UKK)
- Umesh Chaudhari (UKK)
- Hector Keun (IC)
- Jim Ellis (IC)
- Mathieu Vinken (VUB)
- Robim Rodrigues (VUB)
- Vera Rogiers (VUB)
- Laxmikanth Kollipara (ISAS)
- Albert Sickman
- Jan Hengstler (IFADO)
- Andre Schrattenholz (PSY)